In SUM149 triple negative breast cancer cells and in BT474 ERBB2+ breast cancer cells expression of an activated form of STAT3; an activated form of AKT; or an activated form of MEK1 inhibited the lethality of [ruxolitinib + MMF] treatment (Figure 4A, p < 0.05). This evidence concerns the gene MAP2K1 and breast cancer.